The arrival of this new monoclonal antibody will provide a second curative treatment for patients infected with Covid-19. To date, it is the only treatment with a monoclonal antibody authorized as curative and whose neutralizing activity should be preserved once morest the Omicron variant.
Xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing 40 kg or more) with coronavirus disease 2019 (Covid-19) who do not require oxygen supplementation and are at increased risk. of progression to a severe form of Covid-19.
The use of this monotherapy must be done in accordance with the therapeutic use protocol (PUT) defined by the HAS and include virological monitoring.
To date, Xevudy and Ronapreve are administered in health establishments, due to the monitoring of at least one hour which must be set up following administration. Evusheld is available on an outpatient basis for prophylaxis, on hospital prescription (retrocession).
